The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Phase I Study in Advanced Cancer Patients of a Diversified Prime-and-Boost Vaccination Protocol Using Recombinant Vaccinia Virus and Recombinant Nonreplicating Avipox Virus to Elicit Anti–Carcinoembryonic Antigen Immune Responses
Abstract
PURPOSE: This trial sought to determine, for the first time, the validity in human vaccinations of using two different recombinant vaccines in diversified prime-and-boost regimens to enhance T-cell responses to a tumor antigen. PATIENTS AND METHODS: Eighteen patients with advanced tumors expressing carcinoembryonic antigen (CEA) were randomized to receive either recombinant vaccinia (rV)-CEA followed by three avipox-CEA vaccinations, or avipox-CEA (three times) followed by one rV-CEA vaccination. Subsequent vaccinations in both cohorts were with avipox-CEA. Immunologic monitoring was performed using a CEA peptide and the enzyme-linked immunospot assay for interferon gamma production. RESULTS: rV-CEA followed by avipox-CEA was superior to the reverse order in the generation of CEA-specific T-cell responses. Further increases in CEA-specific T-cell precursors were seen when local granulocyte-macrophage colony-stimulating factor (GM-CSF) and low-dose interleukin (IL)-2 were given with subsequent vaccinations. The treatment was extremely well tolerated. Limited clinical activity was seen using vaccines alone in this patient population. Antibody production against CEA was also observed in some of the treated patients. CONCLUSION: rV-CEA was more effective in its role as a primer of the immune system; avipox-CEA could be given up to eight times with continued increases in CEA T-cell precursors. Future trials should use rV-CEA first followed by avipox-CEA. Vaccines specific to CEA are able to generate CEA-specific T-cell responses in patients without significant toxicity. T-cell responses using vaccines alone may be inadequate to generate significant anticancer objective responses in patients with advanced disease. Cytokines such as GM-CSF and IL-2 may play a key role in generating such responses.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lymphokine Production by Human T Cells in Disease States
Romagnani, S. (1994) · Annual Review of Immunology · doi:10.1146/annurev.immunol.12.1.227 · Cited by 1,343
Carcinoembryonic antigen, a human tumor marker, functions as an intercellular adhesion molecule
Benchimol, S., Fuks, A., Jothy, S., Beauchemin, N., Shirota, K., & Stanners, C. P. (1989) · Cell · doi:10.1016/0092-8674(89)90970-7 · Cited by 974
Tsang, K. Y., Zaremba, S., Nieroda, C. A., Zhu, M. Z., Hamilton, J. M., & Schlom, J. (1995) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/87.13.982 · Cited by 498
Self-citationDisis, M., Bernhard, H., Shiota, F., Hand, S., Gralow, Jr., Huseby, E., Gillis, S., & Cheever, M. (1996) · Blood · doi:10.1182/blood.v88.1.202.202 · Cited by 329
A triad of costimulatory molecules synergize to amplify T-cell activation.
Hodge, J. W., Sabzevari, H., Yafal, A. G., Gritz, L. R., Lorenz, M. G., & Schlom, J. (1999) · PubMed · Cited by 297
Self-citationKantor, J., Irvine, K., Abrams, S., Kaufman, H., Dipietro, J., & Schlom, J. (1992) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/84.14.1084 · Cited by 210
Self-citationZaremba, S., Barzaga, E., Zhu, M., Soares, N., Tsang, K. Y., & Schlom, J. (1997) · PubMed · Cited by 204
Self-citationHodge, J. W., McLaughlin, J. P., Kantor, J. A., & Schlom, J. (1997) · Vaccine · doi:10.1016/s0264-410x(96)00238-1 · Cited by 201
Self-citationPellegrini, P., Berghella, A. M., Beato, T. D., Cicia, S., Adorno, D., & Casciani, C. U. (1996) · Cancer Immunology, Immunotherapy · doi:10.1007/s002620050244 · Cited by 190
Scheibenbogen, C., Lee, K. H., Mayer, S., Stevanović, S., Moebius, U., Herr, W., Rammensee, H., & Keilholz, U. (1997) · PubMed · Cited by 124
Cited by
Cancer immunotherapy: moving beyond current vaccines
Rosenberg, S. A., Yang, J. C., & Restifo, N. P. (2004) · Nature Medicine · doi:10.1038/nm1100 · Cited by 2,972
Progress in human tumour immunology and immunotherapy
Rosenberg, S. A. (2001) · Nature · doi:10.1038/35077246 · Cited by 1,325
Parkhurst, M. R., Yang, J. C., Langan, R. C., Dudley, M. E., Nathan, D.-A. N., Feldman, S. A., Davis, J. L., Morgan, R. A., Merino, M. J., Sherry, R. M., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2010.272 · Cited by 1,020
Cancer vaccines: between the idea and the reality
Finn, O. J. (2003) · Nature Reviews Immunology · doi:10.1038/nri1150 · Cited by 636
(2013) · Advances in Cancer Research · doi:10.1016/b978-0-12-407190-2.00007-1 · Cited by 594
Going viral with cancer immunotherapy
Lichty, B. D., Breitbach, C. J., Stojdl, D. F., & Bell, J. C. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3770 · Cited by 581
Garnett, C. T., Palena, C., Chakarborty, M., Tsang, K.-Y., Schlom, J., & Hodge, J. W. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1525 · Cited by 557
Self-citationRosenberg, S. A., Sherry, R. M., Morton, K. E., Scharfman, W. J., Yang, J. C., Topalian, S. L., Royal, R. E., Kammula, U., Restifo, N. P., Hughes, M. S., et al. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.9.6169 · Cited by 465
Immunotherapy of cancer in 2012
Kirkwood, J. M., Butterfield, L. H., Tarhini, A. A., Zarour, H., Kalinski, P., & Ferrone, S. (2012) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20132 · Cited by 436
Chakraborty, M., Abrams, S. I., Coleman, C. N., Camphausen, K., Schlom, J., & Hodge, J. W. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0073 · Cited by 435
Self-citationGulley, J. L., Arlen, P. M., Bastian, A., Morin, S., Marte, J., Beetham, P., Tsang, K.-Y., Yokokawa, J., Hodge, J. W., Ménard, C., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2062 · Cited by 370
Self-citationKeilholz, U., Weber, J., Finke, J. H., Gabrilovich, D. I., Kast, W. M., Disis, M. L., Kirkwood, J. M., Scheibenbogen, C., Schlom, J., Maino, V. C., et al. (2002) · Journal of Immunotherapy · doi:10.1097/00002371-200203000-00001 · Cited by 298
Self-citationMarshall, J. L., Gulley, J. L., Arlen, P. M., Beetham, P. K., Tsang, K.-Y., Slack, R., Hodge, J. W., Doren, S., Grosenbach, D. W., Hwang, J., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.10.206 · Cited by 297
Self-citationCurrent Developments in Cancer Vaccines and Cellular Immunotherapy
Ribas, A., Butterfield, L. H., Glaspy, J. A., & Economou, J. S. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.06.041 · Cited by 295
Arlen, P. M., Gulley, J. L., Parker, C., Skarupa, L., Pazdur, M., Panicali, D., Beetham, P., Tsang, K. Y., Grosenbach, D. W., Feldman, J., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2059 · Cited by 287
Self-citationTherapeutic Cancer Vaccines: Current Status and Moving Forward
Schlom, J. (2012) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djs033 · Cited by 282
Self-citationViral vector-based therapeutic cancer vaccines
Larocca, C., & Schlom, J. (2011) · The Cancer Journal · doi:10.1097/ppo.0b013e3182325e63 · Cited by 222
Self-citationViral vectors for vaccine applications
Choi, Y., & Chang, J. (2013) · Clinical and Experimental Vaccine Research · doi:10.7774/cevr.2013.2.2.97 · Cited by 112
Therapeutic cancer vaccines: From initial findings to prospects
Song, Q., Zhang, C.-D., & Wu, X.-H. (2018) · Immunology Letters · doi:10.1016/j.imlet.2018.01.011 · Cited by 106
Gulley, J. L., Madan, R. A., Tsang, K.-Y., Arlen, P. M., Camphausen, K., Mohebtash, M., Kamrava, M., Schlom, J., & Citrin, D. (2011) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2011.615741 · Cited by 26
“The vaccine schema consists of a vaccinia-based vaccine as an initial priming dose, and subsequent boosting with fowlpox results in enhanced immune activation [17,18].”
BackgroundResultSelf-citation
Metadata
- Authors
- Marshall, J. L., Hoyer, R. J., Toomey, M. A., Faraguna, K., Chang, P., Richmond, E., Pedicano, J. E., Gehan, E., Peck, R. A., Arlen, P., Tsang, K. Y., & Schlom, J.
- Venue
- Journal of Clinical Oncology
- Published
- 2000-12-01
- Volume
- 18
- Issue
- 23
- Pages
- 3964-3973
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1960833366
- Cited by
- 357
- References
- 15
- FWCI
- 9.45
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.